SelectQuote, Inc. (SLQT) - 10-Q Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for SelectQuote, Inc. for the three and nine months ended March 31, 2025. SelectQuote is a technology-enabled, direct-to-consumer distribution platform for insurance policies (Senior, Life, Auto & Home) and healthcare services (SelectRx, Population Health, SelectPatient Management). The company operates three reportable segments: Senior, Healthcare Services, and Life.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Mar 31, 2025 | 3 Months Ended Mar 31, 2024 | 9 Months Ended Mar 31, 2025 | 9 Months Ended Mar 31, 2024 |
|---|---|---|---|---|
| Total Revenue | $408,160 | $376,400 | $1,181,492 | $1,014,567 |
| Net Income (Loss) | $26,022 | $8,551 | $34,712 | $(3,108) |
| Net Income Attributable to Common Shareholders | $20,235 | $8,551 | $28,925 | $(3,108) |
| Diluted EPS | $0.03 | $0.05 | $0.13 | $(0.02) |
| Operating Cash Flow (9 Months) | $25,816 | $(4,759) | $25,816 | $(4,759) |
| Total Debt (Gross) | $391,484 | $683,334 | $391,484 | $683,334 |
| Cash & Restricted Cash | $86,222 | $42,690 | $86,222 | $42,690 |
Segment Performance (9 Months 2025 vs 2024):
- Senior: Revenue decreased 4% to $517.9M; Adjusted EBITDA increased 11% to $153.9M.
- Healthcare Services: Revenue increased 59% to $528.7M (driven by SelectRx); Adjusted EBITDA increased 96% to $13.5M.
- Life: Revenue increased 8% to $125.0M; Adjusted EBITDA increased 52% to $19.7M.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 8% quarter-over-quarter and 17% year-to-date, primarily driven by a 60% increase in Pharmacy revenue ($518.2M) due to a 41% increase in SelectRx members. This offset a 4% decline in Commissions and other services revenue.
- Profitability: The company returned to profitability, reporting Net Income of $26.0M for the quarter compared to $8.6M in the prior year. This was significantly aided by a $33.0M gain from the change in fair value of warrant liabilities.
- Capital Structure: In February 2025, the company completed a $350.0M Senior Non-Convertible Preferred Stock transaction. Proceeds were used to repay $260.0M of Term Loans and $40.0M of the Revolving Credit Facility. Total debt decreased from $683.3M to $391.5M.
- Interest Expense: Net interest expense decreased 16% for the quarter and 4% year-to-date due to debt repayments and a lower cost of capital following the securitization transaction.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted the successful expansion of the Healthcare Services segment, specifically SelectRx, which is now a primary revenue driver. The Senior segment saw a decrease in approved policies (down 8% QoQ) and a decline in Lifetime Value (LTV) per policy due to carrier mix shifts and persistency issues. The Life segment stabilized with growth in final expense premiums.
Risks and Contingencies:
- Legal Proceedings: The company is subject to a securities class action lawsuit (dismissed in April 2025, but plaintiffs filed a notice of appeal in May 2025) and a qui tam action regarding sales and marketing practices filed by the U.S. Attorney's Office in May 2025. The company denies allegations and plans to defend vigorously.
- Warrant Liability: Significant non-cash gains/losses related to the fair value of warrant liabilities (Eleventh Amendment Warrants and Senior Non-Convertible Preferred Stock Warrants) impact net income volatility.
- Debt Covenants: The company must maintain compliance with financial covenants under its Senior Secured Credit Facility and Indenture, including asset coverage and minimum liquidity ratios.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the impact of the $33.0M gain in fair value of warrants on net income and assess the sustainability of earnings without this non-cash item.
- Senior Segment Persistency: Investigate the causes of the 8% decrease in LTV per approved policy and the decline in approved policies in the Senior segment.
- Healthcare Services Margins: Review the gross margin trajectory of the rapidly growing SelectRx pharmacy business, as COGS increased 58% year-to-date.
- Preferred Stock Terms: Review the dividend accretion (14.5% per annum) and redemption terms of the new $350M Senior Non-Convertible Preferred Stock.
- Legal Exposure: Monitor the status of the appealed securities class action and the qui tam False Claims Act investigation.